Login / Signup

Diamine oxidase supplementation improves symptoms in patients with histamine intolerance.

Wolfgang J SchnedlMichael SchenkSonja LacknerDietmar EnkoHarald ManggeFlorian Forster
Published in: Food science and biotechnology (2019)
Histamine intolerance (HIT) is thought to be caused by a disproportionate amount of histamine in the body. The enzyme diamine oxidase (DAO) is considered for the gastrointestinal degradation of histamine. For this open-label interventional pilot study, we identified 28 patients with HIT. For 4 weeks, they were instructed to take DAO capsules before meals. Then, throughout a follow-up period, they were instructed not to take the DAO. We used a questionnaire that included 22 symptoms, which were divided into 4 categories, as well as a symptom severity score. All symptoms improved significantly during the oral supplementation of DAO. During the follow-up period, without DAO supplementation, the symptoms sum scores increased again. The symptom intensity score was reduced for all symptoms. We have demonstrated, a significant reduction of every HIT-related symptom and its intensity due to DAO oral supplements. The ClinicalTrials.gov identifier (NCT number) is NCT03298568.
Keyphrases
  • sleep quality
  • open label
  • clinical trial
  • patient reported
  • high intensity
  • randomized controlled trial
  • squamous cell carcinoma
  • cross sectional
  • study protocol
  • phase ii